The ability to accurately predict how cancer patients will respond to chemotherapy before treatment could mean a future of personalized cancer medicines. Researchers at the Lawrence Livermore National Laboratory and the University of California, Davis, are working on such a test. Mike Malfatti, a biomedical scientist at the lab, says they’re doing this using their accelerator mass spectrometer, or AMS.
"What we do here at the lab with AMS is a technique that can measure rare isotopes at very low levels and what that gives us an advantage of is we can actually do human studies and be able to trace compounds in humans, which can’t be done very many other places because they don’t have the technology that we have here."
The goal is to develop a test that can predict how a patient will react to a particular drug.
"If you give a drug to someone and they’re not responding to it, but they’re getting the bad side effects, that’s not good. The population that might not respond, you can go and prescribe a different drug."